![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
North Eastern Germany Society of Gynaecologic Oncology |
Information provided by: | North Eastern Germany Society of Gynaecologic Oncology |
ClinicalTrials.gov Identifier: | NCT00170573 |
Pegylated liposomal doxorubicin (PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limiting toxicity and have an impact on patients' quality of life (QoL). The primary aim of this study was to optimise the toxicity profile by choosing a biweekly schedule of PLD Furthermore, QoL was investigated. Secondary objective of this study was to evaluate the response rates of this new regimen.
Condition | Intervention | Phase |
Ovarian Cancer |
Drug: Caelyx |
Phase II |
MedlinePlus related topics: | Cancer Ovarian Cancer |
Drug Information available for: | Doxorubicin Doxorubicin hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 32005000 |
First Received: | September 9, 2005 |
Last Updated: | April 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00170573 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|
![]() |